Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 3/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.34 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.34 |
| ▸ | NPY4R | P50391 | 4/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.34 |
| ▸ | NPY2R | P49146 | 1/20 | 0.34 |
| ▸ | FURIN | P09958 | 4/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.32 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22668644 | 1.00 | FAP (0.34) | FAPLTB4RNPY5RNPY4RNPY1R | |
| SCHEMBL18909056 | 0.92 | NPY5R (0.35) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL17722913 | 0.92 | NPY5R (0.37) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20864068 | 0.92 | NPY5R (0.35) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22694922 | 0.91 | FAP (0.37) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL22267878 | 0.91 | FAP (0.37) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL18909025 | 0.91 | FAP (0.37) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL20887767 | 0.90 | FURIN (0.35) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL24335031 | 0.87 | FAP (0.34) | FAPNPY5RNPY4RNPY1RNPY2R | |
| SCHEMBL23789219 | 0.86 | FAP (0.44) | FAPNPY5RNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | NOVARTIS AG (CH) | 2021-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163620-A1 | TRISPECIFIC BINDING MOLECULES AGAINST CANCERS AND USES THEREOF | CD2, CD4, CD22 | FAP 2120/4885LTB4R 2564/4885NPY5R 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.